

HCV/HBV Co-Infection: Hepatitis B reactivation

Nezam Afdhal, MD
Professor of Medicine
Harvard Medical School

Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Patients with Chronic Hepatitis C and Hepatitis B Coinfection: A Phase 3 Study in Taiwan

Chun-Jen Liu, Wan-Long Chuang, I-Shyan Sheen, Horng-Yuan Wang, Chi-Yi Chen, Kuo-Chih Tseng, Ting-Tsung Chang, Benedetta Massetto, Jenny C. Yang, Gregory Camus, Deyuan Jiang, Steven J. Knox, Diana M. Brainard, John G. McHutchison, Tsung-Hui Hu, You-Chun Hsu, Gin-Ho Lo, Chi-Jen Chu, Jyh-Jou Chen, Cheng-Yuan Peng, Ron-Nan Chien, Pei-Jer Chen

Abstract PS-098

Study Design



- Multicenter, open-label study at 14 sites in Taiwan
- Key inclusion criteria
  - GT 1 or 2 HCV-infected adults with HBV coinfection
  - HBsAg positive
  - Not currently on HBV treatment (>6 months)
  - Up to 50% may have had compensated cirrhosis
- Long-term follow-up through post-treatment Week 108

Liu CJ, et al. 52nd EASL; Amsterdam, Netherlands; April 19-23, 2017. Abst. PS-098.

Demographics and Baseline Characteristics

		LDV/SOF 12 weeks N=111
HCV	Mean age, y (range)	55 (32–76)
	Male, n (%)	42 (38)
	Mean BMI, kg/m^2 (range)	25 (17–34)
	IL28B CC, n (%)	85 (77)
	GT 1 / GT 2, n (%)	68 (61) / 43 (39)
	HCV treatment experienced, n (%)	37 (33)
	Mean baseline HCV RNA, $\log_{10}$ IU/mL (range)	5.9 (3.8–7.1)
	Cirrhosis, n (%)	18 (16)
	Mean ALT, U/L (range)	68 (17–281)
HBV	HBsAg positive, n (%)	110* (99)
	HBeAg positive, n (%)	1 (<1)
	GT B/ GT C n (%)	37 (33) / 5 (5)
	GT Missing†	69 (62)
	HBV treatment experienced, n (%)	5 (4)
	Mean baseline HBV DNA, $\log_{10}$ IU/mL (range)	2.1 (1.3–5.8)
	Baseline HBV DNA <LLOQ, n (%)	37 (33)

*1 patient changed HBsAg status between screening and baseline; †HBV genotype could not be determined if HBV DNA <5000 IU/mL

Liu CJ, et al. 52nd EASL; Amsterdam, Netherlands; April 19-23, 2017. Abst. PS-098.

Results: SVR12



- 18 patients had cirrhosis, 37 patients had prior HCV treatment, 46 patients had RASs at baseline (n=39 only NS5A; n=2 only NS5B; n=5 both NS5A and NS5B)

Liu CJ, et al. 52nd EASL; Amsterdam, Netherlands; April 19-23, 2017. Abst. PS-098.

Results: HBV Reactivation, Criteria

n, %	Overall N=111	BL HBV DNA <LLOQ n=37	BL HBV DNA ≥LLOQ n=74
Increase to ≥LLOQ	31 (28)	31 (84)	—
+ ALT >2x ULN	0	0	—
Increase >1 – <2 $\log_{10}$ IU/mL	37 (33)	11 (30)	26 (35)
+ ALT >2x ULN	1 (<1)	0	1 (1)
Increase ≥2 $\log_{10}$ IU/mL (any visit)	24 (22)	11 (30)	13 (18)
+ ALT >2x ULN	4 (4)	0	4 (5)

- No patient had AEs of jaundice, liver decompensation, liver failure or liver transplant

ULN: male 43 U/L; female 34 U/L

Liu CJ, et al. 52nd EASL; Amsterdam, Netherlands; April 19-23, 2017. Abst. PS-098.

Results:
Two Asymptomatic Patients Started HBV Therapy

60-year-old female, HCV GT 1b, HBeAg negative, with cirrhosis

- HBV DNA increased from 1.54log$_{10}$ IU/mL (BL) to 3.8log$_{10}$ IU/mL at Day 57 (Week 8)
- Associated with ALT increase from nadir value of 41 to 71 IU/mL
- Started HBV treatment on study Day 71



61-year-old male, HCV GT 2, HBeAg negative, without cirrhosis

- HBV DNA increased from 2.28log$_{10}$ IU/mL (BL) to 5.95log$_{10}$ IU/mL 30 days post last dose (post-treatment Week 4)
- Associated with ALT increase from nadir value of 47 to 115 IU/mL
- Started HBV treatment during post-treatment follow-up Week 5



Liu CJ, et al. 52nd EASL; Amsterdam, Netherlands; April 19-23, 2017. Abst. PS-098.

Conclusions

- LDV/SOF for 12 weeks achieved 100% SVR12 rate in patients with HBV and HCV GT 1 or 2 infection
- LDV/SOF for 12 weeks was well tolerated with no treatment discontinuation due to AEs
- Treatment with LDV/SOF for 12 weeks was associated with “silent” HBV viral reactivation in 63% of patients (70/111)
  - No patient experienced clinical signs or symptoms of HBV reactivation
  - 5 (5%) patients had concomitant increase in ALT; 2 (2%) patients started HBV therapy
  - Higher HBV DNA and ALT were associated with asymptomatic clinical HBV reactivation

Liu CJ, et al. 52nd EASL; Amsterdam, Netherlands; April 19-23, 2017. Abst. PS-098.